NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company developing high-quality biosimilar products, today disclosed two additional biosimilars in active development. The products are biosimilar candidates referencing Opdivo ® (nivolumab) and Keytruda ® (pembrolizumab). These biosimilars reference two antibody products that bl
September 1, 2020
· 3 min read